ABBV monthly performance report
View ABBV's monthly returns, drawdown, and seasonality trends — updated every month.
ABBV monthly report
—
Key takeaways
- AbbVie (ABBV) closed November 2026 at $295.03, up 0.05% for the month and +27.01% over the trailing 12 months.
- Year-to-date, ABBV is +29.12%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +22.51% versus its 200-day moving average ($240.82), a bullish technical signal.
- Over the past three years, ABBV has outperformed the S&P 500 by +41.43%, with a relative strength index reading of 124.2.
- Win rate over the trailing 39 months stands at 66.7% — 26 positive months versus 13 negative months.
AbbVie ended November 2026 at $295.03, posting a monthly return of +0.05%. The S&P 500 returned −0.18% over the same window, leaving relative performance at +0.23%.
The current quarter stands at +12.78% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +22.51% versus the 200-day moving average ($240.82).
Year-to-date, ABBV is +29.12% against SPY +10.62%, a gap of +18.50%. The stock is currently −2.61% below its 52-week high, with maximum 3-year drawdown at −21.46%.
| Period | ABBV | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.20% | −0.36% | +0.56% |
| 1 Week | +1.28% | +2.59% | −1.32% |
| 1 Month | +0.05% | −0.18% | +0.23% |
| 3 Months | +17.86% | −2.37% | +20.22% |
| 6 Months | +39.98% | +0.83% | +39.15% |
| YTD | +29.12% | +10.62% | +18.50% |
| 12 Months | +27.01% | +12.25% | +14.76% |
| 3 Years | +112.80% | +71.37% | +41.43% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | +15.58% |
| #2 | Feb 2025 | +13.67% |
| #3 | Oct 2026 | +12.73% |
| #4 | Aug 2025 | +11.31% |
| #5 | Sep 2025 | +10.05% |
| Rank | Month | Return |
|---|---|---|
| #1 | Apr 2024 | −10.69% |
| #2 | Nov 2024 | −10.27% |
| #3 | Apr 2025 | −6.88% |
| #4 | Mar 2026 | −6.29% |
| #5 | Oct 2025 | −5.83% |
| Quarter | Return |
|---|---|
| Q3 2025 | +24.74% |
| Q4 2025 | −1.32% |
| Q1 2026 | −4.81% |
| Q2 2026 | +15.70% |
| Q3 2026 | +3.95% |
| Q4 2026 (QTD) | +12.78% |
| Year | Return |
|---|---|
| 2023 | −4.11% |
| 2024 | +14.67% |
| 2025 | +28.58% |
| 2026 | +29.12% |
| Metric | Value |
|---|---|
| 52-Week High | $302.93 (2026-11-05) |
| 52-Week Low | $191.00 (2026-04-29) |
| Current Price | $295.03 |
| 200-Day Moving Average | $240.82 |
| Price vs 200DMA | +22.51% |
| 3-Year Maximum Drawdown | −21.46% (2025-04-21) |
| Current Drawdown from 52W High | −2.61% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 124.2 |
| 3-Year Excess Return vs S&P 500 | +41.43% |
| RS Peak | 125.8 (Nov 2026) |
| RS Trough | 86.8 (May 2026) |
| Status | Outperforming Benchmark |
Frequently asked questions
What was ABBV's return for this report period?
ABBV returned +0.05% in the latest monthly window ending 2026-11-13.
Has ABBV outperformed SPY year to date?
YTD ABBV: +29.12% vs SPY: +10.62%.
What is ABBV's 12-month return?
+27.01% over the trailing 12 months.
Is ABBV above or below its 200-day moving average?
Price is +22.51% versus 200DMA ($240.82).
What is the maximum drawdown in the 3-year window?
−21.46% on 2025-04-21.